Patents
Literature
13 results about "Survivin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded by the BIRC5 gene. Survivin is a member of the inhibitor of apoptosis (IAP) family. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. This has been shown by disruption of survivin induction pathways leading to increase in apoptosis and decrease in tumour growth. The survivin protein is expressed highly in most human tumours and fetal tissue, but is completely absent in terminally differentiated cells. These data suggest survivin might provide a new target for cancer therapy that would discriminate between transformed and normal cells. Survivin expression is also highly regulated by the cell cycle and is only expressed in the G2-M phase. It is known that Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. The molecular mechanisms of survivin regulation are still not well understood, but regulation of survivin seems to be linked to the p53 protein. It also is a direct target gene of the Wnt pathway and is upregulated by beta-catenin.
Survivin as biomarker for predicting responsiveness to cancer treatment
The present invention relates to a method of determining the responsiveness of a cancer patient to treatment with a compound that inhibits a KRAS protein or a KRAS protein mutant or treatment with a compound that inhibits the interaction between MDM2 and p53, the method comprising measuring the survivin level in a first sample obtained from the patient prior to treatment with the compound, measuring the level of survivin in a second sample obtained from the patient during or after treatment with the compound, comparing the level of survivin in the second sample to the level of survivin in the first sample, and determining the level of survivin in the second sample when compared to the level of survivin in the first sample. When the survivin level in the second sample decreases, it is determined that the patient is responsive to treatment with the compound. The invention further relates to the use of survivin in compounds for determining the inhibition of KRAS protein or KRAS protein mutants, or in compounds for inhibiting the interaction between MDM2 and p53, or a pharmaceutical formulation comprising said compound that inhibits a KRAS protein or a KRAS protein mutant or said compound that inhibits an interaction between MDM2 and p53 in a method of treating cancer.
Owner:BOEHRINGER INGELHEIM INT GMBH
Separated tumor specific TCR specifically binding to MHC / Survivin epitope complex and application thereof
The invention discloses a separated tumor specific TCR specifically combined with an MHC / Survivin epitope complex and application thereof, and belongs to the field of cancer immunotherapy, the separated tumor specific TCR specifically combined with the MHC / Survivin epitope complex comprises a TCR alpha chain, the TCR alpha chain comprises a CDR1 with an amino acid sequence of SEQ ID NO: 1, a CDR2 with an amino acid sequence of SEQ ID NO: 2 and a CDR3 with an amino acid sequence of SEQ ID NO: 3; a TCR [beta] chain comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5, and a CDR3 having the amino acid sequence of SEQ ID NO: 6. The TCR can accurately distinguish tumor cells from normal cells, the off-target effect risk is greatly reduced, and immune damage to normal tissue is avoided.
Owner:XIAMEN UNIV
Separated tumor specific TCR specifically binding to MHC / Survivin epitope complex and application thereof
The invention discloses a separated tumor specific TCR specifically combined with an MHC / Survivin epitope complex and application thereof, and belongs to the field of cancer immunotherapy, the separated tumor specific TCR specifically combined with the MHC / Survivin epitope complex comprises a TCR alpha chain, the TCR alpha chain comprises a CDR1 of an amino acid sequence of SEQ ID NO: 1, a CDR2 of an amino acid sequence of SEQ ID NO: 2 and a CDR3 of an amino acid sequence of SEQ ID NO: 3; a TCR [beta] chain comprising a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO: 5, and a CDR3 having the amino acid sequence of SEQ ID NO: 6. The TCR can accurately distinguish tumor cells from normal cells, the off-target effect risk is greatly reduced, and immune damage to normal tissue is avoided.
Owner:AFFILIATED STOMATOLOGICAL HOSPITAL OF XIAMEN MEDICAL COLLEGE (XIAMEN STOMATOLOGICAL HOSPITAL)
Survivin targeting polypeptides for detection and treatment of cancer
Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
Owner:UNIVERSITY OF CHICAGO
Composition associated with baculoviral inhibitor of apoptosis protein 5, and preparation method therefor and use thereof
PCT designated stageWO2026067851A1Peptide/protein ingredientsMicroencapsulation basedInhibitor of apoptosisTumor specific
A composition comprising a nucleic acid encoding a human survivin polypeptide, which contains at least three mutations compared with a natural human survivin polypeptide. The composition is capable of inducing tumor-specific humoral or cellular immune responses.
Owner:CANSINO (SHANGHAI) BIOLOGICAL RES CO LTD
Survivin degraders for targeted cancer treatment
PCT designated stageWO2025207582A1Organic active ingredientsOrganic chemistryCancer targetingOncology
Owner:UNIVERSITY OF TOLEDO
Variant survivin vaccine for treatment of myeloma
The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC +1
A protein chip for early warning of liver cancer and application thereof
This invention provides a protein chip for early warning of liver cancer and its application. The protein chip includes an antigen set; the antigen set includes antigens; the antibodies corresponding to the antigens are at least one of 61 selected from GNA11, GNAS, IDH1, MSH2, NPM1, PAX5, PTCH1, PTEN, SRSF2, Survivin, CAST, PAIP1, PRKCZ, RAD23A, RUNX1T1, SARS, TP53, APEX2, RCSD1, and AIF1; the protein chip is used for early warning assessment of liver cancer, and the early warning assessment steps include: collecting serum from the target population, using the protein chip to detect the serum to obtain detection data, and then determining whether they belong to a low-risk, medium-risk, or high-risk population based on a risk warning model; the protein chip systematically detects tumor-related autoantibody risk factor signals using high-throughput technology for early warning detection of liver cancer.
Owner:GUANGZHOU RENXIN MEDICAL TECHNOLOGY CO LTD
Method for determining radiotherapy sensitivity of nasopharyngeal carcinoma
PCT designated stageWO2025156148A1Medical automated diagnosisStatistical analysisNasopharyngeal cancer
A method for determining the radiotherapy sensitivity of nasopharyngeal carcinoma. The molecular marker is Survivin, and determining Survivin to be the molecular marker for the radiotherapy sensitivity of nasopharyngeal carcinoma comprises the following steps: step 1, literature research; step 2, a cell line experiment; step 3, an animal model experiment; step 4, clinical sample verification; step 5, statistical analysis; step 6, optimization of a method for evaluating the radiotherapy sensitivity; step 7, mechanism research; step 8, construction of a prediction model for radiotherapy sensitivity; and step 9, multi-center research verification.
Owner:JIANGSU CANCER HOSPITAL
Composition associated with baculovirus apoptosis inhibiting protein 5 as well as preparation method and application of composition
PendingCN121759470APeptide/protein ingredientsMicroencapsulation basedTumor specificCell immune response
The present invention relates to a composition comprising a nucleic acid encoding a human-derived survivin polypeptide comprising at least three mutations compared to a natural human-derived survivin polypeptide, said composition being capable of eliciting a tumor-specific humoral or cellular immune response.
Owner:CANSINO (SHANGHAI) BIOLOGICAL RES CO LTD
A method for preparing a multifunctional nanocomposite delivery system CEL-TPP@siSurvivin / TDNP NPs and its application in breast cancer therapeutics.
This invention discloses a method for preparing a multifunctional nanocomposite delivery system CEL-TPP@siSurvivin / TDNP NPs and its application in breast cancer treatment. The system is constructed by bridging triphenylphosphine-modified CEL with carboxyl-modified TPP, followed by electrostatic self-assembly of the product with negatively charged siSurvivin to form a nanocore, which is then encapsulated in turmeric-derived exosomes. This delivery system exhibits uniform spherical shape, a smooth surface, and good serum stability and cellular uptake capacity. TPP modification enables it to specifically target mitochondria, disrupt membrane potential, and synergistically knock down the survivin gene with siRNA, significantly promoting tumor cell apoptosis. This multifunctional nanocomposite delivery system overcomes the problem of poor water solubility of CEL and protects siRNA from nuclease degradation, achieving a highly efficient and synergistic anti-tumor effect.
Owner:NANJING NORMAL UNIVERSITY
PH-sensitive targeted nano drug delivery system containing Survivin siRNA and ZnO
The invention discloses a siRNA delivery carrier CCM-CS / ZnO (at) siSurvivin with pH responsiveness and tumor targeting property, a preparation method thereof, physicochemical properties such as form and structure thereof, encapsulation efficiency and drug release behavior thereof, cell uptake efficiency, tumor targeting ability, lysosome escape ability, gene silencing efficiency, apoptosis promoting ability, tumor cell growth inhibition ability thereof, and application of the siRNA delivery carrier CCM-CS / ZnO (at) siSurvivin. The invention discloses the synergistic anti-tumor capability of Survivin siRNA and ZnO, and further discloses the in-vivo targeting property of the Survivin siRNA and ZnO, the effect of inhibiting the growth of BALB / c tumor-bearing nude mouse tumors and the in-vivo safety of the Survivin siRNA and ZnO. Therefore, the target delivery vector has important application in the field of gene therapy of tumors.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
